https://pkdsignal.com/index.ph....p/three-year-well-de
Analysis of the innovaTV-204 trial indicated that TV monotherapy achieved an objective response rate of 24%, comprising 7% complete responses and 17% partial responses. In the month of September 2021, the US Food and Drug Administration (FDA) granted expedited approval for the utilization of TV in the treatment of individuals suffering from recurrent or metastat
Like
Comment
Share
